About IncellDx
IncellDx is a Healthcare company based in Menlo Park (United States) founded in 2009. Molecular diagnostic assays and kits for infectious diseases are developed. IncellDx has raised $9.5 million across 3 funding rounds from investors including Bioreference. IncellDx offers products and services including HPV E6, E7 mRNA Probe, CMV mRNA Probe, Hybridization Core Reagents, in cellPREP Homogenizer, and Anti PD-L1 Antibody. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Viral. Its competitors include BioLife Solutions, GenScript and Fluent BioSciences; 2 of its 3 listed competitors have raised funding.
Company details
IncellDx was founded in 2009 and is headquartered in Menlo Park, United States. Molecular diagnostic assays and kits targeting infectious diseases such as human papillomavirus (HPV), cytomegalovirus (CMV), and HIV are developed and marketed. Consumables supporting flow cytometry applications are also offered. Operations focus on the diagnostics sector, providing tools for clinical and research use in infectious disease detection.
- Headquarters Menlo Park, United States
- SectorsHealthcare
- Website incelldx.com
- Social LinkedIn X Facebook
- Total Equity Funding$9.5M (USD)
in 3 rounds
- Latest Funding Round$500K (USD), Series B
Jul 2024
- Investors
Products & Services of IncellDx
IncellDx offers a comprehensive portfolio of products and services, including HPV E6, E7 mRNA Probe, CMV mRNA Probe, Hybridization Core Reagents, in cellPREP Homogenizer, and Anti PD-L1 Antibody.
Detects HPV mRNA for cell analysis applications.
Identifies CMV mRNA in single cells.
Supports multiplex RNA detection processes.
Prepares tissue for single cell suspension.
Detects PD-L1 protein in cells.
Funding Insights of IncellDx
IncellDx has successfully raised a total of $9.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $500 thousand completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.5M
- Total Rounds 3
- Last Round Series B — $500,000
- First Round $3M
(Jun 2010)
- Investors Count 1
All 3 funding rounds of IncellDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $500,000 | Series B | – | – | – |
| May 2012 | $6M | Series B | – | – | |
| Jun 2010 | $3M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in IncellDx
IncellDx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bioreference.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pathology laboratory services are operated through a nationwide chain. | 1981 | bioreference.com | Elmwood Park, United States |
Investor details for IncellDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IncellDx
12 people are tracked at IncellDx (8 in leadership, 3 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Daren Abe | Director of Financial Operations | Leadership |
Bruce K. Patterson | CEO & Founder | Leadership |
Ron Blum | Chief Marketing Officer | Leadership |
Eric Hass | COO | Leadership |
Brian Francisco | VP of R&D / Technical Services | Leadership |
Brian Brothen | Chief Commercial Officer | Leadership |
Carol Penfold-Patterson | Founder and VP of Marketing | Leadership |
Dan Casey | Sr. Vice President, Strategic Development And Operations | Leadership |
John Stark | Scientific Advisor | Board & advisors |
Alanee Shaheen | Scientific Advisor | Board & advisors |
Rodrigo Mora-Rodriguez | Scientific Advisor | Board & advisors |
Debra Luff | Business Development Manager/ US | Team |
Complete people profiles for IncellDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IncellDx
3 dated milestones of IncellDx across 15 years, from founding to its latest funding, stage changes and deals.
- Founded IncellDx is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series B, of $500K.
Competitors of IncellDx
IncellDx has 3 listed competitors in our database, 2 of them funded. They include BioLife Solutions, GenScript and Fluent BioSciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biolifesolutions.com | 1987 | Bothell, United States | 685 | Tissue hypothermic storage and cryopreservation freeze media are developed. | ||
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| fluentbio.com | 2018 | Watertown, United States | $19M | Proprietary reagents for single-cell genetic analysis are developed. |
Detailed competitors of IncellDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of IncellDx
Websites that share an audience with IncellDx (incelldx.com).
Websites whose visitors overlap most with IncellDx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
analcancerfoundation.org | analcancerfoundation.org | 100% | #1,522,647 | – | |
tgcsthai.com | tgcsthai.com | 99% | – | ||
cancercell.org | cancercell.org | 98% | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as IncellDx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Incelldx
Complete news archive for IncellDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IncellDx
IncellDx was founded in 2009 and raised its 1st funding round 1 year after it was founded.
IncellDx is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
IncellDx is a funded company, having raised a total of $9.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Jun 2010.
IncellDx was founded in 2009 and is headquartered in Menlo Park, United States. Molecular diagnostic assays and kits targeting infectious diseases such as human papillomavirus (HPV), cytomegalovirus (CMV), and HIV are developed and marketed. Consumables supporting flow cytometry applications are also offered. Operations focus on the diagnostics sector, providing tools for clinical and research use in infectious disease detection.
IncellDx's top competitors include BioLife Solutions, GenScript and Fluent BioSciences.
IncellDx offers HPV E6, E7 mRNA Probe, CMV mRNA Probe, Hybridization Core Reagents, in cellPREP Homogenizer, and Anti PD-L1 Antibody.
IncellDx has 1 investor. Key investors include Bioreference.